Literature DB >> 10593352

Long-term remission of refractory stiff-man syndrome after treatment with intravenous immunoglobulin.

H Khanlou1, G Eiger.   

Abstract

The stiff-man syndrome is a rare neuromuscular disorder characterized by progressive rigidity, stiffness, and intermittent spasm of axial and extremity muscles. Its etiology is unknown. Different therapeutic regimens have been used with variable success. We present a case of refractory stiff-man syndrome, in which the symptoms were successfully controlled by the administration of intravenous immunoglobulin (IVIg). This case gives evidence that IVIg can be a safe and an efficient treatment of refractory stiff-man syndrome. The exact indication for and the cost-effectiveness of IVIg in the treatment of this rare entity remain to be determined.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10593352     DOI: 10.4065/74.12.1231

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  4 in total

Review 1.  Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.

Authors:  Goran Rakocevic; Mary Kay Floeter
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

Review 2.  Intravenous immunoglobulin in neurological disease: a specialist review.

Authors:  C M Wiles; P Brown; H Chapel; R Guerrini; R A C Hughes; T D Martin; P McCrone; J Newsom-Davis; J Palace; J H Rees; M R Rose; N Scolding; A D B Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

Review 3.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

4.  Stiff-person Syndrome.

Authors:  Olavo M. Vasconcelos; Marinos C. Dalakas
Journal:  Curr Treat Options Neurol       Date:  2003-01       Impact factor: 3.598

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.